Seretide is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate:
Or
The recommended dose of Seretide Evohaler 25/50mcg, 25/125mcg or 25/250mcg is two inhalations, twice daily.
Seretide Evohaler comes in three different doses allowing flexibility of dosing for your patient with asthma at low, medium and high dose steroid1.
GSK has reduced the list price for Seretide Evohaler 25/125mg and 25/250mcg between August 2018 and January 2019. These prices changes have been updated in the January 2019 Drug Tariff 4.
The Seretide Evohaler list price reductions are great news for patients with asthma who prefer a MDI and even better news for those who are already using a Seretide Evohaler.
| 25/50mcg 120 Doses | 25/125mcg 120 Doses | 25/250mcg 120 Doses | |
|---|---|---|---|
| BTS ICS Classification | Low | Medium | High |
| Price | £18.00 | £23.45 | £29.32 |
| Price Reduction (since August 2018) | No change | 33% | 50% |
| £ Reduction (since August 2018) | No change | £11.55 | £30.16 |
Seretide has a wealth of patient and physician experience with over 108 million patient treatment years3
The original ICS/LABA - Seretide has proven efficacy in Asthma for nearly 20 years2
Seretide 25/50 mcg Evohaler is the only MDI licensed in paediatric asthma for children 4 years and upwards, which can be used with both the Volumatic and Aerochamber1
At mid dose, Seretide Evohaler 25/125mcg is £5.87 (20%) less expensive than Fostair 100/6 mcg5.
At high dose, Seretide Evohaler 25/250mcg is the same price as Fostair 200/6 mcg at £29.325.
Cost savings are no longer a driver to switch away from Seretide Evohaler to Fostair Inhaler, allowing for choice of inhaler to be based on patient preference.
compared to Sirdupla6...
does not have a license for paediatric asthmais not available in a low dose (25/50 mcg) inhalercannot be used in mild asthma does not have the option of three doses therefore patients cannot be stepped down to the lowest dose of ICS as appropriatecontains ethanol and therefore may not be suitable for all patient groupsis not licensed for use with a Volumatic spacerThe device for patients who prefer an MDI, or when you believe a patient would benefit from an MDI.
Seretide 25/50 mcg Evohaler is the only MDI licensed in paediatric asthma for children 4 years and upwards, which can be used with both the Volumatic and Aerochamber1.
Remove the mouthpiece cover and check the mouthpiece inside and outside to see that it is clean and free of objects.
Shake the inhaler 4 or 5 times to ensure that any loose objects are removed and that the contents of the inhaler are evenly mixed.
Hold the inhaler upright with your thumb on the base, below the mouthpiece. Breathe out as far as is comfortable.
Place the mouthpiece in your mouth between your teeth and close your lips firmly around it, do not bite.
Breathe in through your mouth, just after starting to breathe in, press firmly down on the top of the cannister to release a puff of medicine. Do this while still breathing in steadily and deeply.
Hold your breath, take the inhaler from your mouth and your finger from the top of the Inhaler. Continue holding your breath a few seconds, or as long as comfortable.
To review the estimated financial savings of the Seretide list price change for your LHE, please visit value.gsk.com
If you have an active Seretide Rebate contract please log into our value.gsk.com site for more information about what the recent Seretide price changes mean to your LHE.
If you are not registered, and you are a NHS medicine manager, respiratory commissioner or in an equivalent role, you can register quickly and easily by visiting value.gsk.com
Asthma Control Test (ACT) pad questionnaire to measure the impact of Asthma on a person’s life.
Order now
Evohaler Demonstration device for healthcare professionals to show patients how to use the Evohaler device correctly.
Order now
How to Use Patient Leaflet pad to teach patients how to use their Evohaler on its own and with a Volumatic Spacer.
Order nowAdverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
Seretide is a registered trademark of the GlaxoSmithKline group of companies
B.A. Last updated: January 2019. UK/SFC/0016/18(1)
What is Seretide